Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Harksel

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|April 1, 1987
[Effect of secondary bronchopulmonary diseases on the performance and course of rehabilitation of patients with myocardial infarct]J Schauer, B Harksel, K Harksel
Zeitschrift Fur Geburtshilfe Und Neonatologie|May 1, 1997
[Postpartum ovarian vein thrombosis]U Göretzlehner, B Harksel, L C Horn
Journal of Cancer Research and Clinical Oncology|January 13, 2006
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)W Pönisch, P S Mitrou, K Merkle, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|April 1, 1987
[Effect of secondary bronchopulmonary diseases on the performance and course of rehabilitation of patients with myocardial infarct]J Schauer, B Harksel, K Harksel
Zeitschrift Fur Geburtshilfe Und Neonatologie|May 1, 1997
[Postpartum ovarian vein thrombosis]U Göretzlehner, B Harksel, L C Horn
Journal of Cancer Research and Clinical Oncology|January 13, 2006
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)W Pönisch, P S Mitrou, K Merkle, et al.
Pageof 1